Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
Date:7/23/2014

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. 

Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the viability, proliferation and migration of these cancer cells.

Idelalisib is an oral therapy indicated in combination with rituximab, a monoclonal antibody, for patients with relapsed or refractory CLL for whom rituximab alone would be considered appropriate therapy. In October 2013, a Phase 3 study evaluating idelalisib in combination with rituximab in previously-treated CLL patients not fit for standard chemotherapy was stopped early because interim analysis was showing significant improvement in progression-free survival as well as median overall survival compared to placebo plus rituximab.

Idelalisib was also approved today as a monotherapy for patients with relapsed FL and SLL who have received at least two prior systemic therapies. FDA granted accelerated approval for FL and SLL based on overall response rate. 

"We have been eagerly awaiting the approval of this therapy as these are patients for whom there are few other good treatment options," said Lee Greenberger, Ph.D., LLS's chief scientific officer. "LLS funded research contributed to the understanding of the PI3K pathway in B cell malignancies beginning in 1999; this allowed the identification and clinical development of inhibitors of this target. LLS exists to find cures and ensure access to treatments for blood cancer patients, and any new advance that brings the potential to help save more lives is good news."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

Contact: Andrea Greif
Senior Director of Communications
(914)821-8958 (p)
914)772-3027 (c)
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
2. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
7. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
8. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
9. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
10. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
11. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LODI, N.J. , Feb. 4, 2016  Montoya ... Pinnacle Professional in the field of Pharmaceuticals. Montoya is ... . ... and supplies, Becton Dickinson provides healthcare institutions, ... medical equipment throughout fifty countries across the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... --> --> GAAP results: ... million, up $5.1 million or 4.1% from the third ... from the fourth quarter of 2014. Revenue for the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced that ... donate to Give To Cure’s campaign that is crowdfunding clinical trials to help find ... share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been ... user interface design and the developer has fixed known bugs within the app. Calls ... on their phone while not consuming any of their device’s battery power or memory. ...
Breaking Medicine News(10 mins):